Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ipilimumab by Bristol-Myers Squibb for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
Ipilimumab by Bristol-Myers Squibb for Ovarian Cancer: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Ipilimumab by Bristol-Myers Squibb for Neuroendocrine Tumors: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase...
Ipilimumab by Bristol-Myers Squibb for Vaginal Cancer: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Vaginal Cancer. According to GlobalData, Phase...
Ipilimumab by Bristol-Myers Squibb for Uterine Cancer: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...
Ipilimumab by Bristol-Myers Squibb for Gallbladder Cancer: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase...
Ipilimumab by Bristol-Myers Squibb for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...
Ipilimumab by Bristol-Myers Squibb for Soft Tissue Sarcoma: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...
Ipilimumab by Bristol-Myers Squibb for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According...
Ipilimumab by Bristol-Myers Squibb for Refractory Multiple Myeloma: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...
Ipilimumab by Bristol-Myers Squibb for Glioblastoma Multiforme (GBM): Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...
Ipilimumab by Bristol-Myers Squibb for Gliosarcoma: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II...
Ipilimumab by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...
Ipilimumab by Bristol-Myers Squibb for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Ipilimumab by Bristol-Myers Squibb for Uveal Melanoma: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase...
Ipilimumab by Bristol-Myers Squibb for Metastatic Uveal Melanoma: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...
Ipilimumab by Bristol-Myers Squibb for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...